Stephen D. Silberstein

4.6k total citations · 1 hit paper
58 papers, 3.2k citations indexed

About

Stephen D. Silberstein is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Stephen D. Silberstein has authored 58 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Psychiatry and Mental health, 29 papers in Pathology and Forensic Medicine and 15 papers in Physiology. Recurrent topics in Stephen D. Silberstein's work include Migraine and Headache Studies (53 papers), Trigeminal Neuralgia and Treatments (25 papers) and Sympathectomy and Hyperhidrosis Treatments (15 papers). Stephen D. Silberstein is often cited by papers focused on Migraine and Headache Studies (53 papers), Trigeminal Neuralgia and Treatments (25 papers) and Sympathectomy and Hyperhidrosis Treatments (15 papers). Stephen D. Silberstein collaborates with scholars based in United States, Germany and Italy. Stephen D. Silberstein's co-authors include David W. Dodick, Richard B. Lipton, Eric Ashman, Charles E. Argoff, F. G. Freitag, Peter J. Goadsby, William B. Young, Alastair Macrae, Jes Olesen and Jesper Filtenborg Tvedskov and has published in prestigious journals such as Neurology, Nature Reviews Neurology and Headache The Journal of Head and Face Pain.

In The Last Decade

Stephen D. Silberstein

57 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults

2012 617 citations Stephen D. Silberstein, David W. Dodick et al. Neurology profile →

Peers

Countries citing papers authored by Stephen D. Silberstein

Since Specialization

Citations

This map shows the geographic impact of Stephen D. Silberstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen D. Silberstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen D. Silberstein more than expected).

Fields of papers citing papers by Stephen D. Silberstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen D. Silberstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen D. Silberstein. The network helps show where Stephen D. Silberstein may publish in the future.

Co-authorship network of co-authors of Stephen D. Silberstein

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen D. Silberstein. A scholar is included among the top collaborators of Stephen D. Silberstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen D. Silberstein. Stephen D. Silberstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management 2024 ·Nature Reviews Neurology ·Patricia Pozo‐Rosich, Alicia Alpuente, Stephen D. Silberstein, Rami Burstein	4
2	Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis 2023 ·Headache The Journal of Head and Face Pain ·Stewart J. Tepper, Richard B. Lipton, Stephen D. Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David W. Dodick, Andrea Wang, Sunfa Cheng, Jan Klatt, Daniel D. Mikol	5
3	A Novel Virtual-Based Comprehensive Clinical Approach to Headache Care 2023 ·Journal of Clinical Medicine ·(unknown), Stephen D. Silberstein, Peter McAllister	2
4	Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System 2022 ·Advances in Therapy ·Stephen D. Silberstein, (unknown), Joshua M. Cohen, Sanjay Gandhi, Michael J. Seminerio, (unknown), (unknown), (unknown), Andrew Blumenfeld	24
5	Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale 2022 ·BioDrugs ·Fred Cohen, Hsiangkuo Yuan, Stephen D. Silberstein	26
6	Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials 2021 ·The Journal of Headache and Pain ·Stephen D. Silberstein, Joshua M. Cohen, Ronghua Yang, Sanjay Gandhi, Evelyn Du, (unknown), Michael J. Marmura	8
7	Intravenous ibuprofen for acute treatment of migraine: A double‐blind, randomized, placebo‐controlled pilot study 2021 ·Headache The Journal of Head and Face Pain ·Hsiangkuo Yuan, John Curran, Scott W. Keith, Mary Hopkins, Stephen D. Silberstein	5
8	Long-term Efficacy of Fremanezumab in Patients With Chronic or Episodic Migraine Who Were Inadequate Responders to Initial Fremanezumab Treatment (2406) 2021 ·Neurology ·Stephen D. Silberstein, (unknown), (unknown), (unknown), Joshua M. Cohen, Michael J. Seminerio, (unknown), Andrew Blumenfeld	1
9	Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study 2020 ·The Journal of Headache and Pain ·Stephen D. Silberstein, Merle L. Diamond, Nada Hindiyeh, David M. Biondi, Roger Cady, Joe Hirman, Brent Allan, Susan Pederson, Barbara Schaeffler, Jeff Smith	72
10	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults 2020 ·Cephalalgia ·Hans‐Christoph Diener, Cristina Tassorelli, David W. Dodick, Stephen D. Silberstein, Richard B. Lipton, Messoud Ashina, Werner J. Becker, Michel D. Ferrari, Peter J. Goadsby, Patricia Pozo‐Rosich, Shuu‐Jiun Wang, Timothy T. Houle, Thomas C. van den Hoek, Daniele Martinelli, Gisela M. Terwindt	117
11	Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension 2020 ·Cephalalgia ·Richard B. Lipton, Stewart J. Tepper, Stephen D. Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David W. Dodick, (unknown), Gregory A. Rippon, Sunfa Cheng, Daniel D. Mikol	25
12	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition 2019 ·Cephalalgia ·Hans‐Christoph Diener, Cristina Tassorelli, David W. Dodick, Stephen D. Silberstein, Richard B. Lipton, Messoud Ashina, Werner J. Becker, Michel D. Ferrari, Peter J. Goadsby, Patricia Pozo‐Rosich, Shuu‐Jiun Wang, Jay Mandrekar	161
13	Migraine prevention 2007 ·Practical Neurology ·DW Dodick, Stephen D. Silberstein	61
14	Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: A randomized, placebo-controlled, double-blind, 12-week pilot study 2006 ·Clinical Therapeutics ·Stephen D. Silberstein, Joseph Hulihan, (unknown), (unknown), D. C. Jordan, (unknown), Marc Kamin	55
15	HORMONE-RELATED HEADACHE 2001 ·Medical Clinics of North America ·Stephen D. Silberstein	47
16	Safety of Divalproex Sodium in Migraine Prophylaxis: An Open‐Label, Long‐term Study 1999 ·Headache The Journal of Head and Face Pain ·Stephen D. Silberstein, Stephen D. Collins, (unknown)	84
17	DRUG-INDUCED HEADACHE 1998 ·Neurologic Clinics ·Stephen D. Silberstein	15
18	Migraine Aura and Prodrome 1995 ·Seminars in Neurology ·Stephen D. Silberstein, William B. Young	39
19	Safety and Efficiency of Ergotamine Tartrate and Dihydroergotamine in the Treatment of Migraine and Status Migrainosus [RETIRED] 1995 ·Neurology ·Stephen D. Silberstein, William B. Young	61
20	Nature of migraine attacks during pregnancy 1994 ·Contemporary ob/gyn ·Stephen D. Silberstein, Jennifer R. Niebyl	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact